Renvistobart clinical trials
Also written BMS-986207.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses renvistobart has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BMS-986207
- 3
Studies by the year they started
3 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Bristol-Myers Squibb (2) · Multiple Myeloma Research Consortium (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses renvistobart has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsCompletedPhase 1/2Bristol-Myers SquibbNCT02913313Written as BMS-986207How we knowReport a problem
- Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGITTerminatedPhase 1/2Multiple Myeloma Research ConsortiumNCT04150965Written as Anti-TIGIT + Pomalidimide + DexamethasoneHow we knowReport a problem
- A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerCompletedPhase 2Bristol-Myers SquibbNCT05005273Written as BMS-986207How we knowReport a problem
Tested with established drugs · 2 — they are given beside it
- A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsCompletedPhase 1/2Bristol-Myers SquibbNCT02913313Written as BMS-986207How we knowReport a problem
- A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerCompletedPhase 2Bristol-Myers SquibbNCT05005273Written as BMS-986207How we knowReport a problem
Tested in a combination · 1 — another drug in the study is under test too
Codes
What other systems call renvistobart · ClinicalTrials.gg INT015572
- UNII (FDA) 81J55YFQ16RENVISTOBARTOne source FDA
- NCI Thesaurus C131907RenvistobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 81J55YFQ16 | RENVISTOBART | One source FDA |
| NCI Thesaurus | C131907 | Renvistobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.